Physician profile
Desiree D Wright
NPI 1528713328
$2,745.91
in general payments reported to CMS, 2019-2025
24 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $829 · 2024: $819 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.72 |
| Education | $228.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $703.80 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $341.00 | 2024-2025 | |
| Glaxosmithkline, LLC. | $297.20 | 2023-2025 | Jemperli, Zejula |
| Eisai INC. | $284.45 | 2022-2025 | |
| Astellas Pharma US INC | $241.79 | 2023-2024 | Veozah |
| Tempus Ai, INC | $161.41 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals Lp | $146.72 | 2022-2025 | Lynparza |
| Daiichi Sankyo INC. | $102.29 | 2025 | Enhertu |
| Seagen INC. | $58.79 | 2022-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $46.92 | 2023-2025 | Mychoice Cdx, Myrisk |
| Immunogen, INC. | $44.63 | 2023 | Elahere |
| Davol INC. | $39.13 | 2025 | |
| Pfizer INC. | $33.82 | 2025 | |
| Atricure, INC. | $30.78 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Incyte Corporation | $28.64 | 2025 | Zynyz, Monjuvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $27.55 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.53 | 2023 | Libtayo |
| Baxter Healthcare | $25.48 | 2024 | Perclot |
| Clovis Oncology, INC. | $22.11 | 2022 | |
| Caris Mpi, INC. | $20.57 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $18.60 | 2024 | Rolvedon |
| Morphosys, US INC. | $15.23 | 2023 | Monjuvi |
| Conmed Corporation | $14.75 | 2025 | Abc Handpieces |
| Mirati Therapeutics, INC. | $13.72 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.